Advances in Virology / 2020 / Article / Fig 4

Research Article

HBV Core Promoter Inhibition by Tubulin Polymerization Inhibitor (SRI-32007)

Figure 4

HBV core promoter assay. (a) Schematic of the HBV core promoter assay: (b) and (c) Huh7 cells transfected with plasmid containing HBV core promoter fused to firefly luciferase along with another plasmid encoding renilla luciferase under the control of SV40 promoter were treated with increasing concentrations of SRI-32007 or entecavir, followed by measurement of luciferase activity posttreatment. Ratio of firefly luciferase to the renilla luciferase in Huh7 cells treated with either entecavir (b) or SRI-32007 (c) normalized to the untreated controls (mean ± standard deviation) are shown in the figure. This experiment was repeated twice to confirm the reproducible inhibition of HBV core promoter by SRI-32007. A representative graph from one experiment is shown in the figure. Stars (∗) show statistical significance compared to the untreated control (Dunnett’s multiple comparison test, one-way ANOVA, GraphPad Prism 5).
(a)
(b)
(c)

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.